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Abstract Palmitoylation of eNOS is required for targeting to 
plasmalemmal caveolae and agonist-promoted depalmitoylation 
leads to eNOS translocation, modifying the agonist response. To 
date, one palmitoyl-protein thioesterase (PPT) has been purified 
and cloned. To explore the role of PPT in eNOS palmitoylation, 
we first established that PPT mRNA and protein are expressed 
in endothelial cells. Coexpression of PPT and eNOS in 
heterologous systems (COS and Sf-9 cells) resulted in a marked 
reduction in [3H]palmitate labeling of eNOS. We found, 
however, that co-expression did not alter subcellular targeting 
of eNOS, but that |3H]palmitate incorporation into cellular 
lipids, in particular palmitoyl-CoA, was significantly reduced. 
These results suggest that while PPT expression can significantly 
alter cellular lipid metabolism, it has no effect on eNOS 
palmitoylation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The endothelial isoform of nitric oxide synthase (eNOS) is 
an important determinant of blood pressure homeostasis and 
platelet aggregation [1,2], and is targeted to plasmalemmal 
caveolae consequent to its dual acylation by the fatty acids 
myristate and palmitate [3-5]. In addition to eNOS, many 
other proteins modulating cellular signal transduction, includ-
ing G-protein-coupled receptors, G-proteins and tyrosine kin-
ases are similarly modified by the covalent attachment of fatty 
acids [6-8]. Acylation of these proteins, by N-myristoylation 
and/or thiopalmitoylation, appears to play an important role 
in targeting of signaling proteins to cell membranes, and may 
modulate the cellular response to agonist drugs and hor-
mones. 
N-myristoylation is an essentially irreversible protein mod-
ification catalyzed by well-characterized Af-myristoyltransfer-
ases, and occurs co-translationally (following removal of the 
N-terminal methionine residue) via an amide linkage of the 
14-carbon-saturated fatty acid myristate to the amino-termi-
nal glycine (Gly2) within a specific N-terminal consensus se-
quence [9]. By contrast, protein thiopalmitoylation is an easily 
reversible post-translational modification and involves the for-
mation of a fatty acyl thioester between the 16-carbon-satu-
rated fatty acid palmitate and specific cysteine residues in a 
variety of membrane-targeted signaling proteins [6-8]. Protein 
N-myristoylation alone appears to impart insufficient hydro-
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phobicity to stabilize membrane association of the modified 
protein: many membrane-associated myristoylated proteins 
are further stablized by electrostatic interactions with mem-
brane phospholipids, or by additional post-translational mod-
ifications, including palmitoylation. Palmitoylated proteins 
appear to be exclusively membrane-associated, and the lability 
of the palmitoyl-protein thioester bond appears to facilitate 
the dynamic regulation of protein palmitoylation, and, con-
sequently membrane targeting. For example, agonist-induced 
depalmitoylation of eNOS likely promotes enzyme transloca-
tion from plasmalemmal caveolae, and thereby may impor-
tantly influence the agonist response [10]. 
How are these key regulatory pathways of protein palmi-
toylation and depalmitoylation controlled? No general con-
sensus sequences for protein palmitoylation have been identi-
fied, and the enzymatic machinery involved in protein 
palmitoylation remains incompletely understood. No protein 
palmitoylthiotransferase has been purified to homogeneity, 
and molecular clones encoding this key activity have not yet 
been isolated [11,12]. Recently, however, a single protein pal-
mitoylthioesterase (termed PPT) was purified, and its molec-
ular clone has been isolated and characterized [13,14]. PPT 
was recently discovered to localize in cellular vesicles, presum-
ably lysosomes [15], but the biological functions PPT remain 
somewhat enigmatic, and its potential role in the regulation of 
eNOS entirely unexplored. The purified PPT thioesterase can 
catalyze removal of palmitate from palmitoylated proteins 
such as H-ras, and in addition, PPT has been shown to pos-
sesses acyl-CoA hydrolase activity that can hydrolyze palmi-
toyl-CoA in vitro. Despite these advances in understanding 
the biochemical properties of PPT, the roles of PPT in the 
regulation of palmitoylated proteins within cells are not yet 
completely defined. An essential role for PPT in neuronal 
function was established by the recent discovery that PPT 
deficiency is the cause of the rare and fatal neurodegenerative 
disease, infantile neuronal ceroid lipofuchsinosis [16]. Given 
the rapidly emerging biological role of PPT, it seemed to us 
imperative that the role of this enzyme in the regulation of 
eNOS palmitoylation be defined. In these studies, we first 
establish that PPT is expressed in endothelial cells that express 
eNOS, and and then explore the role of PPT in eNOS palmi-
toylation and subcellular targeting using heterologous expres-
sion systems. 
2. Materials and methods 
2.1. Biological reagents 
Plasmid constructs encoding wild-type eNOS, myristoylation-defi-
cient eNOS (alanine substituted for Gly2, termed myr~, and palmi-
toylation-deficient eNOS (serines substituted for Cys15 and Cys26, 
termed palm-) in the expression vector pBK-CMV (Stratagene) 
have been described previously [3,4]. The plasmid pCMV-PPT con-
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taining the full-length 940 bp bovine PPT cDNA was a kind gift from 
S. Hofmann [14]. A rabbit anti-peptide polyclonal anti-eNOS antise-
rum we have extensively characterized was used for immunoprecipi-
tation of eNOS from cell lysates [3]; a mouse monoclonal anti-eNOS 
antibody (Transduction Laboratories, Lexington, KY) was employed 
for immunoblot analyses. Purified polyclonal rabbit anti-PPT anti-
body was a kind gift of S. Hofmann [14]. Recombinant baculovirus 
constructs encoding eNOS (BV-ecNOS) and PPT (BV-PPT, gift of S. 
Hofmann) have been described previously [14,17]. Purified PPT iso-
lated from baculovirus-infected insect Sf9 cells was a generous gift of 
S. Hofmann. 
2.2. Cell culture and transfection 
COS-7 cells were maintained in culture and transiently transfected 
with eNOS or PPT cDNAs using the DEAE-dextran method; bovine 
aortic endothelial cells were cultured as previously described [18,19] 
and used between passages 6 and 11. Insect Sf-9 cells were maintained 
in spinner culture and infected with recombinant baculovirus as de-
scribed previously [17]. Transfected COS-7 cells or recombinant ba-
culovirus-infected insect Sf9 cells were biosynthetically labeled with 
[3H]palmitic acid, and eNOS was immunoprecipitated and analyzed 
by SDS-PAGE and fluorography exactly as described previously [3,4]. 
NADPH-diaphorase assays of transfected COS-7 and Sf-9 cells were 
performed as previously described [3,17]. Immunoblots using the 
eNOS antibody as probe were analyzed by chemiluminescence accord-
ing to the manufacturer's instructions (Renaissance, DuPont NEN, 
Wilmington, MA). Immunoblot analyses of PPT in endothelial cell 
lysates used a 1:2500 dilution of purified rabbit anti-PPT antibody as 
a primary antibody, and peroxidase-conjugated goat anti-rabbit IgG 
(Pierce) was used for chemiluminescencent detection of PPT. 
2.3. Northern blot analysis 
Total RNA was harvested from confluent BAECs using TRIZOL 
reagent (BRL Life Sciences) following the manufacturer's protocols. 
Agarose electrophoresis and northern blot analyses were performed 
using standard protocols, using as probe a 32P-labeled PPT cDNA 
(obtained from a Pst-1 digest of plasmid pCMV-PPT); filters were 
exposed to Kodak XAR film using intensifying screens at — 70°C 
for 24 h; molecular weight markers (RNA MW II markers) were 
from Boehringer Mannheim Biochemicals. 
2.4. RT-PCR 
Reverse transcription-polymerase chain reaction (RT-PCR) of en-
dothelial cell transcripts were performed as previously described [20]. 
Briefly, total RNA was isolated from confluent BAECs, and cDNA 
was synthesized using Superscript II reverse transcriptase (BRL Life 
Sciences). PCR (30 cycles) was performed using an annealing temper-
ature of 55°C. Forward (5'-TGCTTGTGGCTCTTGGCTCTCG-3') 
and reverse (5'-TGCGGTATATGTCCT-CCCTGAT-3') primers spe-
cific for bovine PPT [14] were predicted to amplify a 574 bp DNA 
fragment. The plasmid encoding PPT was used as a positive control; a 
sample of BAEC RNA identically processed, but otherwise lacking 
reverse transcriptase, provided a negative control. 
2.5. Thin-layer chromatography 
Sf-9 cells from suspension spinner culture were transferred to P-60 
plates and infected with recombinant baculovirus expressing PPT 
(BV-PPT). Seventy-two hours after infection, cells were to biosyntheti-
cally labeled with [3H]palmitate. In parallel, uninfected Sf-9 cells were 
maintained and biosynthetically labeled under identical conditions. 
Extraction of cellular lipids and TLC were performed following pre-
viously described protocols [21]. Liquid scintillation counting con-
firmed that equal 3H-counts were present in lipid extracts from both 
infected and uninfected cells. The lipid extracts were then subjected to 
aqueous extraction to enrich for palmitoyl-CoA, using established 
protocols [21]. Following reverse-phase TLC on KC18 Silica Gel 60 
TLC plates (Whatman) developed in (5:3:2) butanol/water/acetic 
acid, plates were air-dried, sprayed with fluor (En3Hance, DuPont), 
and exposed to Kodak XAR film using intensifying screens at —70°C 
for 12-48 h. 
3. Results 
PPT is expressed by cultured endothelial cells. Experiments 
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Fig. 1. PPT expression in endothelial cells. Left panel: Northern 
blot analysis of RNA extracted from BAEC probed with 32P-labeled 
PPT cDNA, as described in the text. An arrow marks the location 
of the 2.5 kb PPT transcript. The right panel shows an immunoblot 
of BAEC extracts resolved by SDS-PAGE, electroblotted and 
probed with PPT antibody. The arrow indicates the position of PPT 
protein. This experiment was performed twice in duplicate, yielding 
identical results. 
seeking to establish a role for PPT in eNOS palmitoylation 
explored first whether PPT is expressed in endothelial cells 
that express eNOS. Bovine aortic endothelial cells (BAEC) 
have been extensively studied in culture, and are known to 
express eNOS. Northern blots of total RNA obtained from 
confluent BAEC were probed with the full-length 940 bp bo-
vine PPT cDNA and demonstrate a single band at approxi-
mately 2.5 kb (Fig. 1, left panel). This is similar in size to the 
major PPT transcript identified in bovine brain [14]. Expres-
sion of PPT mRNA in BAEC was further confirmed by RT-
PCR experiments: PCR primers for bovine PPT amplified the 
predicted 574 bp product in cDNA prepared from BAEC, 
with appropriate positive and negative controls confirming 
PPT expression in these cells (data not shown). Immunoblot 
analysis of endothelial cells reveals a broad band at ~ 38 kDa 
(Fig. 1, right panel), as previously described in bovine brain 
tissues; this broad band appears to reflect glycosylation of 
PPT [14]. 
3.1. Co-transfection of eNOS and PPT cDNAs into COS-7 
cells 
We next explored the effects of PPT expression on eNOS 
palmitoylation. COS-7 cells, which express neither eNOS nor 
PPT, were utilized to establish a heterologous system to study 
eNOS and PPT co-expression using appropriate expression 
vectors. Our previous work has demonstrated that recombi-
nant wild-type eNOS transfected into COS-7 cells undergoes 
acylation and subcellular targeting to plasmalemmal caveolae 
in a manner essentially identical to that observed in endothe-
lial cells [3,4,10]. COS cells have also been used to study PPT 
processing and activity [14]. We transfected COS-7 cells with 
wild-type eNOS alone, or in combination with wild-type PPT, 
and 48-72 h later performed metabolic labeling with 
[3H]palmitate, followed by immunoprecipitation. Control cells 
were also transfected with either the eNOS palmitoylation-
deficient mutant (palm -), or with the eNOS myristoylation-
deficient mutant (myr~), and processed in parallel by immu-
noprecipitation, SDS-PAGE and fluorography. As shown in 
Fig. 2 (left panel), there is 3H-labeling of wild-type eNOS 
transfected alone, but only trace labeling of eNOS co-trans-
fected with PPT; similar amounts of total eNOS protein in 
each lane were documented by immunoblot analysis, as shown 
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Fig. 2. Effects of PPT expression on [3H]palmitate biosynthetic labeling of eNOS in transfected COS-7 cells. COS-7 cells were transfected with 
cDNAs encoding PPT and/or eNOS, myristoylation deficient eNOS (myr—) or palmitoylation deficient eNOS (palm—). 48-72 h following trans-
fection, cells were labeled for 2 h with [3H]palmitate and harvested. In these experiments, all 3H-labeling of eNOS and of cellular lysates was 
abrogated by treatment with 1 M hydroxylamine (pH 7.0), indicating that the labeling resulted from thioester linkages to [3H]palmitate (data 
not shown). Left panel: Cellular homogenates immunoprecipitated with anti-eNOS serum were analyzed by SDS-PAGE on 7% gels followed 
by fluorography. The film shown was exposed to X-ray film for 1 week at —70°C using intensifying screens. Shown under this panel is are im-
munoblot analyses of these same samples, analyzed in parallel and probed using a monoclonal eNOS antibody. The righthand panel shows the 
parallel analysis of total cellular lysates prepared from the transfected COS-7 cells (10 u,g total protein) and subjected to SDS-PAGE and fluo-
rography. The data shown are representative of four similar experiments. 
below the fluorogram. As expected, no [3H]palmitate labeling 
of eNOS is seen in cells transfected with the palmitoylation-
or myristoylation-deficient mutants of eNOS; eNOS protein 
expression is entirely absent in cells transfected with PPT 
alone. In order to explore whether PPT co-transfection gen-
erally affected protein 3H-palmitoylation, total cellular lysates 
from transfected cells were also examined by SDS-PAGE and 
fluorography (Fig. 2, right panel). There was no significant 
difference in overall 3H-labeling of cellular proteins following 
transfection with PPT. This observation argues against a post-
hoc action of PPT on palmitoylated proteins in the cellular 
lysates. To exclude the possibility that a specific PPT-medi-
ated depalmitoylation of eNOS occurs in cellular lysates, we 
mixed lysates of eNOS transfected COS cells with lysates from 
cells transfected with either PPT or vector alone. We observed 
no difference in 3H-labeling of eNOS following 24 h incuba-
tions (4°C) with either lysate (data not shown). In previous 
studies, we have seen no evidence of post-lysis artifacts follow-
ing co-transfection under similar reaction conditions [22]. 
Interpretation of this negative result is confounded by the 
fact that only about 10% of the COS-7 cells in the dish suc-
cessfully undergo transfection using these protocols, and a 
marked effect on protein labeling in the minority of cells ac-
tually expressing PPT might be obscured by the large majority 
of cells that remain untransfected. In order to overcome this 
limitation, we infected insect Sf-9 cells with recombinant ba-
culovirus expressing eNOS and PPT cDNAs, under condi-
tions we have previously shown to result in expression of 
recombinant enzyme in the majority of treated cells [17]. 
3.2. Infection of Sf-9 cells with baculovirus containing eNOS 
and PPT cDNAs 
We have previously established that recombinant eNOS ex-
pressed in insect Sf-9 cells undergoes myristoylation and pal-
mitylation, and is appropriately targeted to the particulate 
subcellular fraction in infected cells [17]. Recombinant PPT 
expression in insect Sf9 cells has, in similar fashion, been 
characterized by Camp et al. [14], who found that the re-
combinant enzyme is enzymatically active. In our experi-
ments, we found the recombinant baculovirus constructs in-
fected the majority of treated Sf9 cells: ~ 9 0 % of Sf-9 cells 
treated with BV-PPT could be found to express the protein 
(by immunohistochemical analysis), and ~ 5 0 % of the Sf9 
cells treated with BV-eNOS expressed the enzyme (using the 
NADPH-diaphorase assay, as previously described [17]. Sf9 
cells infected with BV-PPT or BV-eNOS, alone or in combi-
nation, were biosynthetically labeled with [3H]palmitate and 
analyzed by immunoprecipitation and by subcellular fraction-
ation, as discussed below. There was strong [3H]palmitate 
labeling of eNOS immunoprecipitated from cells infected 
with the BV-eNOS virus alone, but, co-infection of BV-
eNOS with BV-PPT led to a marked attenuation in eNOS 
3H-labeling, with no change in the total quantity of eNOS 
enzyme expressed (Fig. 3). In order to explore the effects of 
PPT expression on [3H]palmitate labeling of total cellular pro-
teins, we analyzed lysates prepared from biosynthetically la-
beled cells by SDS-PAGE and fluorography (Fig. 3, upper 
panel), and found that 3H-labeling of several proteins, in ad-
dition to eNOS, is attenuated by PPT. This indicates that the 
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Fig. 3. Effects of PPT expression on [3H]palmitate biosynthetic labeling of eNOS in insect Sf-9 cells. Three days after infection with recombi-
nant baculovirus expressing eNOS, PPT or co-infected with both viruses, Sf-9 cells were labeled for 2 h with [3H]palmitate and harvested. The 
upper panel shows the fluorogram of SDS-PAGE analysis both of 3H-labeled total cellular lysates as well as the pattern seen following immu-
noprecipitation of eNOS. The lower panel shows the results of Coomassie Blue staining of cellular lysates of infected cells following SDS-
PAGE, documenting equivalent total protein in cellular lysates as well as similar eNOS content in Sf-9 cells infected with eNOS or with eNOS 
plus PPT. An arrow indicates the position of eNOS. The experiment shown was repeated 3 times with equivalent results. 
effect of PPT on [3H]palmitate labeling is not specific to 
eNOS. 
3.3. Effect of PPT co-expression on eNOS subcellular 
distribution 
The attenuation of [3H]palmitate labeling of cellular pro-
teins induced by PPT might reflect a variety of different mech-
anisms. One possbility is that PPT is directly or indirectly 
promoting the depalmitoylation of diverse palmitoyl-protein 
substrates. An alternative explanation is that PPT expression 
might lead to a decrease in the specific activity of the 
[3H]palmitate in the cellular pool of palmitic acid in trans-
fected cells (plausibly through its previously characterized ac-
tivity as an acyl-CoA hydrolase). These two hypothesis will be 
addressed in turn. We have previously established that the 
palmitoylation-deficient eNOS mutant (palm -) is partially re-
distributed to the soluble subcellular fraction, relative the the 
wild-type enzyme. If the marked decrease in [3H]palmitate 
labeling of eNOS caused by PPT co-expression truly reflects 
an attenuation in the overall level of eNOS palmitoylation 
state, a concordant change in subcellular localization of 
eNOS should be detected. We therefore performed subcellular 
fractionation of lysates prepared from COS-7 cells transfected 
with cDNAs encoding eNOS or PPT, individually or in com-
bination; the myristoylation- and palmitoylation-deficient 
mutants of eNOS served as key controls. (COS-7 cells are 
used for these experiments because we have not yet developed 
recombinant baculovirus expressing the eNOS acylation mu-
tants). Lysates prepared from transfected cells were resolved 
by ultracentrifugation into soluble and particulate fractions, 
and then analyzed by immunoprecipitation with eNOS anti-
serum followed by SDS-PAGE electrophoresis and immuno-
blot analysis (Fig. 4). These experiments showed no difference 
in subcellular localization between eNOS alone or eNOS co-
transfected with PPT. In both cases the majority ( > 95%) of 
eNOS is found in the particulate fraction and less than 5% in 
the soluble fraction (Fig. 4, upper panel). The subcellular 
distribution of the palmitoylation deficient mutant, on the 
other hand, is similar to that reported previously (55% partic-
ulate and 45% soluble), and the myristoylation-deficient mu-
tant was found almost entirely in the soluble fraction. PPT 
expression was not systematically altered by co-expression 
with eNOS, nor was the ratio of particulate to soluble PPT 
changed substantively. The absence of any change in the sub-
cellular distribution of eNOS in the presence of PPT expres-
sion suggests that the decrease in [3H]palmitate labeling of 
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Fig. 4. Effects of PPT co-expression on eNOS subcellular distribution in transfected COS-7 cells. COS -7 cells were transfected with cDNAs en-
coding PPT or eNOS, alone or in combination; the myristoylation deficient eNOS (myr—); or the palmitoylation deficient eNOS (palm—). Sev-
enty-two hours after transfection, the COS-7 cells were harvested and sonicated and subjected to cellular fractionation by ultracentrifugation 
followed by immunoprecipitation with anti-eNOS or anti-PPT antibodies, as described in the text. The top panel shows the immunoblot analy-
sis of a eNOS-immunoprecipitated samples resolved on a 9% polyacrylamide gel and probed with the eNOS monoclonal antibody. The bottom 
panel shows the immunoblot analysis of PPT immunoprecipitated samples resolved on a 12% polyacrylamide gel and probed with PPT antise-
rum. The data shown are representative of three independent and identically designed experiments. 
eNOS seen with PPT coexpression does not result from the 
removal of palmitate from eNOS, but more likely represents a 
change in the specific activity of the [3H]palmitoyl-CoA sub-
strate due to PPT expression in the biosynthetically labeled 
cells. 
3.4. PPT expression in insect Sf9 cells attenuates biosynthetic 
incorporation of f3Hj'palmitate into [3HJpalmitoyl-CoA 
We next explored the effects of PPT on [3H]palmitate bio-
synthetic labeling of cellular lipids. Sf-9 cells, rather than COS 
cells, were studied for this purpose: the majority of Sf9 cells 
become infected with BV-PPT and robustly express the pro-
tein, and there is thus a minimal background of uninfected 
cells. Expression of PPT leads to a reduced incorporation of 
[3H]palmitate labeling of total cellular lipids (Fig. 5), as docu-
mented by TLC of organic extracts of infected and uninfected 
biosynthetically labeled cells. Palmitoyl-CoA was enriched by 
performing an aqueous extraction from the organic phase us-
ing established methodologies [21], and we found a marked 
reduction in 3H-labeled palmitoyl Co A is seen in Sf-9 cells 
expressing PPT compared to wild-type cells. It therefore seems 
most plausible that the marked decrease in 3H-biosynthetic 
labeling of palmitoylated proteins consequent to PPT expres-
sion reflects an attenuation in the specific activity of the cel-
lular [3H]palmitoyl-CoA pool. 
4. Discussion 
The present studies have shown that PPT and eNOS are 
both expressed in endothelial cells, suggesting a possible link 
between these two key proteins. Indeed, PPT co-expression 
with eNOS leads to a marked decrease in [3H]palmitate bio-
synthetic labeling of eNOS. However, this decrease in 
[3H]palmitate labeling of eNOS leads to no change in its sub-
cellular distribution, as is characteristic of the palmitoylation-
deficient mutant eNOS [4]. Instead, the dramatic decrease in 
eNOS [3H]palmitate biosynthetic labeling induced by PPT 
appears to be explainable on the basis of its effects on cellular 
lipid metabolism. The widespread but highly variable tissue 
distribution of PPT might thus importantly influence the 
study of protein palmitoylation in different cell types. 
PPT, the only mammalian acyl thioesterase identified to 
date, posseses the important enzymatic activity of removing 
palmitate from cysteine residues of mature proteins [13,14]. 
However, the other enzymatic activities characteristic of 
PPT, including its activity as an acyl-CoA hydrolase, might 
be anticipated profoundly to affect cellular lipid and proteo-
lipid metabolism, with important consequences for the flux of 
labeled lipids (e.g. [3H]palmitate) into cellular pools in bio-
synthetic labeling experiments. In these studies, we found that 
PPT expression markedly attenuates the [3H]palmitate biosyn-
thetic labeling of eNOS, and of other palmitoylated proteins. 
However, this decrease in short-term biosynthetic protein 
[3H]palmitate labeling of eNOS does not appear to be associ-
ated with an overall decrease in steady-state enzyme palmitoy-
lation (using the surrogate marker of subcellular distribution), 
and the effect can perhaps be best explained by the effects of 
PPT on cellular lipid metabolism. We propose that PPT, per-
haps through its palmitoyl-CoA hydrolase activity, leads to a 
decrease in specific activity of the cellular [3H]palmitoyl CoA 
pool such that after biosynthetic labeling, less [3H]palmitate is 
incorporated into eNOS and other palmitoylated proteins. 
The differential effects of PPT on the 3H-labeling of diverse 
cellular proteins might possibly reflect differences in their suit-
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Fig. 5. Effects of PPT expression on [3H]palmitate incorporation into cellular lipids. Cellular lipids extracted from Sf-9 cells, either uninfected 
or infected with baculovirus expressing PPT, were analyzed by reverse-phase TLC as described in the text. An arrow denotes the position of 
[3H]palmitoyl-CoA which was run in parallel. Scintillation counting of extracts established that samples prepared from infected and uninfected 
cells contained equivalent 3H cpm. This experiment was performed 4 times with equivalent results. 
ability as substrates for PPT, but, in the context of our other 
findings, we feel this more likely represents differences in pal-
mitate turnover for these diverse proteins during the period of 
biosynthetic labeling. Indeed, the predominant membrane as-
socation of eNOS in the presence of co-expressed PPT argues 
against an important effect of PPT on steady-state palmitoy-
lation and myristoylation of eNOS (which acylations are the 
key determinants for eNOS membrane targeting; refs. [3,4]) 
despite the dramatic effects of PPT on the short-term biosyn-
thetic labeling of the protein. It is problematic, however, to 
study longer periods of biosynthetic labeling with [3H]pal-
mitate: prolonged incubation of cells with [3H]palmitate 
is confounded by metabolic conversion of the labeled fat-
ty acid to [3H]myristate and to 3H-labeled amino acids, and 
interpretation of such labeling experiments are dubious 
[21]. 
Biosynthetic labeling with [3H]palmitate has become a 
standard procedure for analyzing the palmitoylation state of 
a variety of proteins [21]. The present studies demonstrate 
that under certain experimental conditions, changes in 
[3H]palmitate biosynthetic labeling of a given protein may 
not reflect actual changes in its palmitoylation state; this 
may be particularly problematic in the characterization of 
candidate protein palmitoylthioesterases, especially those pos-
sessing acyl-CoA hydrolase activity. The mechanism for this 
effect remains speculative, as detailed enzymological studies of 
palmitoylthiotransferases are not yet available. Studies with 
partially purified palmitoylthiotransferases indicate that pal-
mitoyl-CoA can serve as an effective substrate, but the char-
acteristics of purified protein palmitoylthioesterases remain 
incompletely defined [11,12]. 
Reversible palmitoylation is a prominent feature of many 
key signaling proteins in addition to eNOS, including G-pro-
tein alpha subunits, cellular oncogenes, and G-protein-
coupled receptors. The identity of the protein palmitoylthioes-
terase(s) responsible for depalmitoylation of eNOS and of 
other signaling proteins remains obscure, and the identifica-
tion and characterization of additional candidate protein pal-
mitoylthioesterases remain areas of active investigation. 
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